about
Interventions for melanoma in situ, including lentigo malignaSentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanomaInterferon alpha for the adjuvant treatment of cutaneous melanomaBreast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled TrialsSurvivin gene levels in the peripheral blood of patients with gastric cancer independently predict survival.Genetic variation of clock genes and cancer risk: a field synopsis and meta-analysisMultimodal treatment of peritoneal carcinomatosis and sarcomatosis.Multiplexed protein signal pathway mapping identifies patients with rectal cancer that responds to neoadjuvant treatment.Stop-flow technique for loco-regional delivery of antiblastic agents: literature review and personal experience.Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis.Quantitative real-time PCR: a powerful ally in cancer research.Gastrointestinal stromal tumors: from a surgical to a molecular approach.Pharmacokinetics of intraperitoneal cisplatin and doxorubicin.Human miRNome profiling in colorectal cancer and liver metastasis development.DNA array-based gene profiling in tumor immunology.Tumor necrosis factor, cancer and anticancer therapy.Towards the development of tumor necrosis factor (TNF) sensitizers: making TNF work against cancer.Strategies to enhance the anticancer potential of TNF.Cyto-reductive Surgery combined with Hyperthermic Intra-peritoneal Chemotherapy for Peritoneal Surface Malignancies: current treatment and results.Circumventing melanoma chemoresistance by targeting DNA repair.Coinhibitory molecules in cancer biology and therapy.Vitamin B6 and Cancer Risk: A Field Synopsis and Meta-Analysis.Isolated vascular perfusion of human colon with adenocarcinoma.Colorectal metastases to the liver: present status of management.Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma.Decellularized colorectal cancer matrix as bioactive microenvironment for in vitro 3D cancer research.A retrospective analysis of 141 patients with liver metastases from uveal melanoma: a two-cohort study comparing transarterial chemoembolization with CPT-11 charged microbeads and historical treatments.Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic fistula following pancreaticoduodenectomy.Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O.Tumor budding as a risk factor for nodal metastasis in pT1 colorectal cancers: a meta-analysis.Celiomesenteric trunk aneurysm.Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis.Induction of endothelial nitric oxide synthase expression by melanoma sensitizes endothelial cells to tumor necrosis factor-driven cytotoxicity.Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma.Factors Predictive of Nonsentinel Lymph Node Involvement and Clinical Outcome in Melanoma Patients With Metastatic Sentinel Lymph NodeHyperthermic Isolated Perfusion With Low-Dose Tumor Necrosis Factor α and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue SarcomasIsolated limb perfusion for the management limb threatening soft tissue sarcomas: The role of histological type on clinical outcomesAdherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective TIssue CAncer NETwork (CONTICANET)Long-Term Results of Melphalan-Based Isolated Limb Perfusion With or Without Low-Dose TNF for In-Transit Melanoma Metastases
P50
Q24187170-5DFB0361-5C44-4130-B0E4-DC786AEFE619Q24187945-3971B056-69FF-4203-A58C-DEB07A907A93Q24201908-84C661AD-E52A-4DA4-B5D9-20A87234BEEDQ28269986-0F690137-CA8A-4BF2-A9F0-4807A82467B2Q33594454-A7B3F7DB-0665-40E5-9EC1-C2460955DC48Q33618941-A08D0DFF-1F67-4C8A-B86B-2BBB09203FACQ34209903-2DE163B6-E1CC-4046-9FE4-81C41104DB7FQ34289736-EA3CFABD-E039-494F-878C-36AF2E917789Q34825173-249C7925-DBA4-4735-A353-CAD6F418B535Q34976152-FFABF6B3-AE35-4C02-9780-0CD303D25B05Q35134629-B711564B-4D0C-4028-9291-E3FF58C633A6Q35209537-50BA1BBA-FF1E-4577-BE87-B88D26308CACQ35563280-024CE483-1D62-40B3-BCC5-0B413F4C5653Q35814028-50316539-B794-437A-BA33-432F0884F060Q35842904-1E760A35-1AFB-4D8A-96F0-85A3AFBAF531Q36055874-D6A17148-9FFB-40E7-99EA-839D0FB54B9BQ36755826-5FD9B1C9-F78B-45AB-984E-E2BFCBE1BE5AQ36992639-E4423D37-3753-472E-9142-18E922017FBFQ37909714-00153AA1-95C2-4D31-A704-CA82D0478C90Q38025709-F67DE8B5-F686-4936-8A95-A79E54E1638FQ38079081-B468BD88-9165-4701-A52A-26BAD1EB9759Q39219615-E8214DFC-BA1F-40E2-92A9-7E987E2DFA04Q40829660-F831C99C-0E45-4547-9190-7D99085F704EQ41187496-4F0D2950-719C-446F-AC8A-3E5B693E21BAQ43899253-3A112FE6-0C59-4A18-A6C0-B6158B347A33Q47246744-D657FAFE-4DA1-415F-B9BC-B3A28070350EQ47576138-2097A601-6ABB-4961-B6B6-9422269CF1CDQ47953294-F25F79EA-7C7D-43E8-BA63-C47DEDA21C26Q51255044-572D7BDA-C697-47D5-BA91-DC21D600A6C0Q51742663-55181683-E47B-4F25-BCFA-6DEEFDBA5983Q51826893-80D77F46-BA31-4BB1-9AD1-6B5442788858Q53393391-6F462B83-5745-42ED-9925-540A588939C5Q54339982-B995B682-23FE-45C6-B0B5-066DFC3814B0Q54696101-3810E40C-0FCB-43F2-842B-1803A9389231Q54710156-3490E92D-CAC5-4DC0-81F6-605F13ACCBB8Q58486141-F565BFB8-7A47-4CF2-BDCC-3E40D2F23453Q58486156-AAC8CBEC-D4A3-4F6C-AD85-C74BF5946711Q61447463-761A2AE7-D81B-4685-9802-FC5F9C85ADF8Q61447541-DF79AF90-4ABF-4914-85B9-6EBCB57962B6Q61832236-87EE9BAA-A136-46D1-B787-C8982183267A
P50
description
researcher ORCID ID = 0000-0003-2985-992X
@en
name
Pierluigi Pilati
@ast
Pierluigi Pilati
@en
Pierluigi Pilati
@es
Pierluigi Pilati
@nl
type
label
Pierluigi Pilati
@ast
Pierluigi Pilati
@en
Pierluigi Pilati
@es
Pierluigi Pilati
@nl
prefLabel
Pierluigi Pilati
@ast
Pierluigi Pilati
@en
Pierluigi Pilati
@es
Pierluigi Pilati
@nl
P1153
7003533397
P31
P496
0000-0003-2985-992X